BCT Press Release
Skip Ribbon Commands
Skip to main content
Sign In
{{'GLOBAL_MESSAGE_HEADLINE' | translate}}
{{'GLOBAL_MESSAGE_CHOOSE_LANG' | translate}}
en
日本語
中文
{{'GLOBAL_MESSAGE_OR' | translate}}
{{'GLOBAL_MESSAGE_SET_COUNTRY' | translate}}
{{'ELOQUA_BANNER_DECLINE_CONFIRM' | translate}}
{{'ELOQUA_BANNER_DECLINE_CONFIRM_CLOSE' | translate}}
{{'ELOQUA_BANNER_ACCEPT' | translate}}
{{'ELOQUA_BANNER_DECLINE' | translate}}

CEO Antoinette Gawin will serve as Group Managing Executive Officer in Terumo Corporation’s New Executive Officers’ Management System

4/12/2022
Gawin is the only female and the only non-Japanese member in this important role and is tasked with enhancing the company’s competitiveness on a global level

LAKEWOOD, Colo., U.S.A. - Terumo Blood and Cell Technologies, a medical technology company, announces the appointment of Antoinette Gawin to serve as Group Managing Executive Officer (GMEO) for Terumo Corporation (TSE:4543). Terumo is redefining its internal management system to reflect rapidly expanding global operations. Gawin is the President and Chief Executive Officer of the Terumo Blood and Cell Technologies subsidiary. The appointment is effective 1 April 2022.

This announcement comes alongside Terumo's work to enhance its competitiveness on a global scale and achieve its outlined five-year plan, referred to as GS26. Terumo has shifted its business from predominantly "in Japan for Japan" to becoming a global healthcare company. Today, about 67% of Terumo's revenue is generated outside of Japan, driven in part by the growth of Terumo Blood and Cell Technologies under Gawin's leadership and the steady expansion of Terumo's Cardiac and Vascular businesses.

The newly formed GMEO position will directly shape strategy across all Terumo operating entities. Gawin is the only female and only non-Japanese leader ever to serve in this capacity. She will continue participating in Terumo's Executive Management Meeting (EMM) as a core member.

Gawin's vision for Terumo Blood and Cell Technologies led to its successful return to growth, achieving USD 1 billion sales in each of the last three years since she took the helm as CEO. Her vision drives the company's aspiration to serve more patients. She led the strategic shift to blood and beyond, including entrance to the source plasma industry and double-digit growth in the cell and gene therapy sector. The strategic effort to move to blood and beyond also underpins the company's goal to serve unmet medical needs; a recent example is the company's collaboration with Immunicom to launch breakthrough cancer immunotherapy treatment in Europe. Gawin is helping to shape customer environments with an ecosystem of automation, services and enterprise software that improves patient access to safe and adequate blood and cells. The company's upgraded infrastructure and delivery system are foundational and were successfully tested during COVID-19 as production rapidly flexed to meet demand shifts and support the global collection of convalescent plasma.

"Gawin possesses extensive and proven leadership expertise in refocusing businesses around the specific needs of patients and customers while building sustainable growth. She achieves this by orchestrating targeted investments in legacy and new therapies and innovations, including forging new markets in plasma collections," said Shinjiro Sato, President and Chief Executive Officer, Terumo Corporation. "As we continue to expand our operations, we are furthering our commitment to cultivate a globally diverse, equitable and inclusive culture to which Gawin can provide an extraordinary contribution." ​

Gawin says: "I am honored to build on Terumo's 100-year legacy as we work to make healthcare treatments available to more patients by influencing standards of care to ultimately impact lives."

About Terumo Blood and Cell Technologies
Terumo Blood and Cell Technologies is a medical technology company. Our products, software and services enable customers to collect and prepare blood and cells to help treat challenging diseases and conditions. Our employees worldwide believe in the potential of blood and cells to do even more for patients than they do today. This belief inspires our innovation and strengthens our collaboration with customers.

Our customers include blood centers, hospitals, therapeutic apheresis clinics, cell collection facilities, researchers, plasma collection and processing centers, biotech and CAR-T therapy organizations, and private medical practices in over 130 countries across the globe. We have 750+ granted patents, with more than 150 additionally pending.​

We have global headquarters in Lakewood, Colo., U.S.A., along with five regional headquarters, seven manufacturing sites and six innovation and development centers across the globe. Terumo Blood and Cell Technologies is a subsidiary of Terumo Corporation (TSE: 4543), a global leader in medical technology.

 

About Terumo
Terumo (TSE: 4543) is a global leader in medical technology and committed to "Contributing to Society through Healthcare" for 100 years. Based in Tokyo and operating globally, Terumo employs more than 25,000 associates worldwide to provide innovative medical solutions in more than 160 countries and regions. The company started as a Japanese thermometer manufacturer and has been supporting healthcare ever since. Now, its extensive business portfolio ranges from vascular intervention and cardio-surgical solutions, blood transfusion and cell therapy technology, to medical products essential for daily clinical practice such as transfusion systems, diabetes care, and peritoneal dialysis treatments. Terumo will further strive to be of value to patients, medical professionals, and society at large.

{{'SEARCH_MODAL_TITLE' | translate }}
{{'SEARCH_MODAL_OR' | translate }}

{{'SEARCH_MODAL_BROWSE' | translate }} {{'SEARCH_MODAL_ENLABEL' | translate }}
{{'SEARCH_MODAL_CHOOSE_LANGUAGE' | translate }} {{'SEARCH_MODAL_CHANGE_LANGUAGE' | translate }}
{{$index+1}}. {{s.label}}